CA2039449A1 - Vih-1 amorce et methode de detection a l'aide de l'amorce - Google Patents
Vih-1 amorce et methode de detection a l'aide de l'amorceInfo
- Publication number
- CA2039449A1 CA2039449A1 CA002039449A CA2039449A CA2039449A1 CA 2039449 A1 CA2039449 A1 CA 2039449A1 CA 002039449 A CA002039449 A CA 002039449A CA 2039449 A CA2039449 A CA 2039449A CA 2039449 A1 CA2039449 A1 CA 2039449A1
- Authority
- CA
- Canada
- Prior art keywords
- sequence
- hiv
- dna
- sample
- pcr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 64
- 238000001514 detection method Methods 0.000 title claims abstract description 43
- 238000003752 polymerase chain reaction Methods 0.000 claims abstract description 112
- 210000004369 blood Anatomy 0.000 claims abstract description 57
- 239000008280 blood Substances 0.000 claims abstract description 57
- 230000035945 sensitivity Effects 0.000 claims abstract description 21
- 108020004414 DNA Proteins 0.000 claims description 115
- 239000013615 primer Substances 0.000 claims description 85
- 239000000523 sample Substances 0.000 claims description 77
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical class O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 claims description 28
- 108020004707 nucleic acids Proteins 0.000 claims description 26
- 150000007523 nucleic acids Chemical class 0.000 claims description 26
- 102000039446 nucleic acids Human genes 0.000 claims description 26
- 239000000463 material Substances 0.000 claims description 24
- 239000002773 nucleotide Substances 0.000 claims description 22
- 125000003729 nucleotide group Chemical group 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 9
- 108020004566 Transfer RNA Proteins 0.000 claims description 7
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 claims description 6
- 239000005695 Ammonium acetate Substances 0.000 claims description 6
- 229940043376 ammonium acetate Drugs 0.000 claims description 6
- 235000019257 ammonium acetate Nutrition 0.000 claims description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 5
- 230000001413 cellular effect Effects 0.000 claims description 4
- 108020001019 DNA Primers Proteins 0.000 claims description 3
- 239000003155 DNA primer Substances 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 239000003298 DNA probe Substances 0.000 claims description 2
- 239000012876 carrier material Substances 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 244000052769 pathogen Species 0.000 claims 3
- 230000001717 pathogenic effect Effects 0.000 claims 3
- 108020003215 DNA Probes Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 230000001376 precipitating effect Effects 0.000 claims 1
- 241000725303 Human immunodeficiency virus Species 0.000 abstract description 92
- 241000713772 Human immunodeficiency virus 1 Species 0.000 abstract description 30
- 238000012360 testing method Methods 0.000 abstract description 24
- 238000012986 modification Methods 0.000 abstract description 7
- 230000004048 modification Effects 0.000 abstract description 7
- 210000004027 cell Anatomy 0.000 description 27
- 229930010555 Inosine Natural products 0.000 description 26
- 229960003786 inosine Drugs 0.000 description 26
- 230000003321 amplification Effects 0.000 description 23
- 238000003199 nucleic acid amplification method Methods 0.000 description 23
- 230000000652 homosexual effect Effects 0.000 description 19
- 208000030507 AIDS Diseases 0.000 description 16
- 208000031886 HIV Infections Diseases 0.000 description 15
- 238000006243 chemical reaction Methods 0.000 description 15
- 239000000427 antigen Substances 0.000 description 14
- 108091007433 antigens Proteins 0.000 description 14
- 102000036639 antigens Human genes 0.000 description 14
- 238000004458 analytical method Methods 0.000 description 13
- 208000015181 infectious disease Diseases 0.000 description 13
- 101710205625 Capsid protein p24 Proteins 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 208000037357 HIV infectious disease Diseases 0.000 description 12
- 101710177166 Phosphoprotein Proteins 0.000 description 12
- 101710149279 Small delta antigen Proteins 0.000 description 12
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 12
- 238000012408 PCR amplification Methods 0.000 description 11
- 241000700605 Viruses Species 0.000 description 11
- 238000009396 hybridization Methods 0.000 description 11
- 230000001566 pro-viral effect Effects 0.000 description 11
- 238000012216 screening Methods 0.000 description 11
- 210000005087 mononuclear cell Anatomy 0.000 description 10
- 108091034117 Oligonucleotide Proteins 0.000 description 9
- 230000000692 anti-sense effect Effects 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 238000006467 substitution reaction Methods 0.000 description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- 108010062347 HLA-DQ Antigens Proteins 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 230000003612 virological effect Effects 0.000 description 8
- 238000007400 DNA extraction Methods 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 239000000284 extract Substances 0.000 description 7
- 210000005259 peripheral blood Anatomy 0.000 description 7
- 239000011886 peripheral blood Substances 0.000 description 7
- 230000000405 serological effect Effects 0.000 description 7
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 210000004970 cd4 cell Anatomy 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 5
- 239000013592 cell lysate Substances 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 230000009984 peri-natal effect Effects 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 208000031504 Asymptomatic Infections Diseases 0.000 description 4
- 230000004544 DNA amplification Effects 0.000 description 4
- 108010067770 Endopeptidase K Proteins 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- 238000010222 PCR analysis Methods 0.000 description 4
- 238000002944 PCR assay Methods 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 229920001213 Polysorbate 20 Polymers 0.000 description 4
- 101800001690 Transmembrane protein gp41 Proteins 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 230000005540 biological transmission Effects 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 4
- 230000008774 maternal effect Effects 0.000 description 4
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 239000000356 contaminant Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 239000002987 primer (paints) Substances 0.000 description 3
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 206010001513 AIDS related complex Diseases 0.000 description 2
- 208000014644 Brain disease Diseases 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 208000032274 Encephalopathy Diseases 0.000 description 2
- 108010012003 GGCC-specific type II deoxyribonucleases Proteins 0.000 description 2
- 229920002527 Glycogen Polymers 0.000 description 2
- 208000029523 Interstitial Lung disease Diseases 0.000 description 2
- 208000008771 Lymphadenopathy Diseases 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 2
- 208000001388 Opportunistic Infections Diseases 0.000 description 2
- 201000011252 Phenylketonuria Diseases 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 238000000376 autoradiography Methods 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000009352 congenital transmission Effects 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229940096919 glycogen Drugs 0.000 description 2
- 208000034737 hemoglobinopathy Diseases 0.000 description 2
- 238000007901 in situ hybridization Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 208000018555 lymphatic system disease Diseases 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 239000002751 oligonucleotide probe Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 108700004029 pol Genes Proteins 0.000 description 2
- 101150088264 pol gene Proteins 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 108700026220 vif Genes Proteins 0.000 description 2
- 101150059019 vif gene Proteins 0.000 description 2
- ALSQUSUPDQPCQY-UHFFFAOYSA-N (methoxyamino)phosphonous acid Chemical compound CONP(O)O ALSQUSUPDQPCQY-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical group C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 101100074846 Caenorhabditis elegans lin-2 gene Proteins 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 241000581444 Clinidae Species 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 208000027472 Galactosemias Diseases 0.000 description 1
- 108010086786 HLA-DQA1 antigen Proteins 0.000 description 1
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 1
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 1
- 208000019758 Hypergammaglobulinemia Diseases 0.000 description 1
- HAEJPQIATWHALX-KQYNXXCUSA-N ITP Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N1C(N=CNC2=O)=C2N=C1 HAEJPQIATWHALX-KQYNXXCUSA-N 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 208000001019 Inborn Errors Metabolism Diseases 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 101100497386 Mus musculus Cask gene Proteins 0.000 description 1
- 101100101585 Mus musculus Ubqln4 gene Proteins 0.000 description 1
- 241001620634 Roger Species 0.000 description 1
- 241000613130 Tima Species 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000012864 cross contamination Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- OIMXTYUHMBQQJM-UHFFFAOYSA-N ergone Natural products C1=CC2=CC(=O)CCC2(C)C2C1=C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OIMXTYUHMBQQJM-UHFFFAOYSA-N 0.000 description 1
- OIMXTYUHMBQQJM-HSVWHVBGSA-N ergosta-4,6,8(14),22-tetraen-3-one Chemical compound C1=CC2=CC(=O)CC[C@]2(C)[C@@H]2C1=C1CC[C@H]([C@H](C)/C=C/[C@H](C)C(C)C)[C@@]1(C)CC2 OIMXTYUHMBQQJM-HSVWHVBGSA-N 0.000 description 1
- 206010016165 failure to thrive Diseases 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 230000007614 genetic variation Effects 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 206010019847 hepatosplenomegaly Diseases 0.000 description 1
- 230000000423 heterosexual effect Effects 0.000 description 1
- 238000004770 highest occupied molecular orbital Methods 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 208000016245 inborn errors of metabolism Diseases 0.000 description 1
- 208000015978 inherited metabolic disease Diseases 0.000 description 1
- 238000011850 initial investigation Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000003771 laboratory diagnosis Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000005551 perinatal transmission Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- -1 polypropylene Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 150000004032 porphyrins Chemical group 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 238000013102 re-test Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000012954 risk control Methods 0.000 description 1
- 208000007056 sickle cell anemia Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 208000010648 susceptibility to HIV infection Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/702—Specific hybridization probes for retroviruses
- C12Q1/703—Viruses associated with AIDS
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- AIDS & HIV (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA002039449A CA2039449A1 (fr) | 1991-03-28 | 1991-03-28 | Vih-1 amorce et methode de detection a l'aide de l'amorce |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA002039449A CA2039449A1 (fr) | 1991-03-28 | 1991-03-28 | Vih-1 amorce et methode de detection a l'aide de l'amorce |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2039449A1 true CA2039449A1 (fr) | 1992-09-29 |
Family
ID=4147304
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002039449A Abandoned CA2039449A1 (fr) | 1991-03-28 | 1991-03-28 | Vih-1 amorce et methode de detection a l'aide de l'amorce |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA2039449A1 (fr) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU670804B2 (en) * | 1992-08-24 | 1996-08-01 | Akzo N.V. | Improved method for nucleic acid amplification |
| EP0727497A1 (fr) * | 1995-02-17 | 1996-08-21 | F. Hoffmann-La Roche Ag | Amorces et sondes pour détection de VIH |
| WO1997042344A1 (fr) * | 1996-05-03 | 1997-11-13 | Institut Für Medizinische Molekulardiagnostik Gbrmbh | Procede pour l'analyse genetique du sang et moyen pour sa mise en oeuvre |
-
1991
- 1991-03-28 CA CA002039449A patent/CA2039449A1/fr not_active Abandoned
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU670804B2 (en) * | 1992-08-24 | 1996-08-01 | Akzo N.V. | Improved method for nucleic acid amplification |
| EP0727497A1 (fr) * | 1995-02-17 | 1996-08-21 | F. Hoffmann-La Roche Ag | Amorces et sondes pour détection de VIH |
| WO1997042344A1 (fr) * | 1996-05-03 | 1997-11-13 | Institut Für Medizinische Molekulardiagnostik Gbrmbh | Procede pour l'analyse genetique du sang et moyen pour sa mise en oeuvre |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Cassol et al. | Use of dried blood spot specimens in the detection of human immunodeficiency virus type 1 by the polymerase chain reaction | |
| Jackson et al. | Human immunodeficiency virus type 1 detected in all seropositive symptomatic and asymptomatic individuals | |
| Albert et al. | Simple, sensitive, and specific detection of human immunodeficiency virus type 1 in clinical specimens by polymerase chain reaction with nested primers | |
| Simmonds et al. | Human immunodeficiency virus-infected individuals contain provirus in small numbers of peripheral mononuclear cells and at low copy numbers | |
| JP5205346B2 (ja) | Ｈｉｖ−１の増幅及び検出試薬 | |
| Cassol et al. | Stability of dried blood spot specimens for detection of human immunodeficiency virus DNA by polymerase chain reaction | |
| Guatelli et al. | Nucleic acid amplification in vitro: detection of sequences with low copy numbers and application to diagnosis of human immunodeficiency virus type 1 infection | |
| Cunningham et al. | Comparison of human immunodeficiency virus 1 DNA polymerase chain reaction and qualitative and quantitative RNA polymerase chain reaction in human immunodeficiency virus 1-exposed infants | |
| Damond et al. | Plasma RNA viral load in human immunodeficiency virus type 2 subtype A and subtype B infections | |
| KR100615407B1 (ko) | Ｈｉｖ-1의 모든 아형의 증폭 및 검출시 프라이머 및프로브로서 사용할 수 있는 핵산 서열 | |
| US5589333A (en) | In situ polymerase chain reaction | |
| Chiodi et al. | Human immunodeficiency virus type 1 is present in the cerebrospinal fluid of a majority of infected individuals | |
| Krivine et al. | A comparative study of virus isolation, polymerase chain reaction, and antigen detection in children of mothers infected with human immunodeficiency virus | |
| US5403707A (en) | Diagnostic compositions, elements, methods and test kits for amplification and detection of retroviral DNA using primers having matched melting temperatures | |
| Whetsell et al. | Comparison of three nonradioisotopic polymerase chain reaction-based methods for detection of human immunodeficiency virus type 1 | |
| Damond et al. | Quantification of proviral load of human immunodeficiency virus type 2 subtypes A and B using real-time PCR | |
| US6475729B1 (en) | Nucleic acid amplification and detection methods using rapid polymerase chain reaction cycle | |
| US6709813B1 (en) | Diagnostic compositions, elements, methods and test kits for amplification and detection of human CMV DNA using primers having matched melting temperatures | |
| Wages Jr et al. | Clinical performance of a polymerase chain reaction testing algorithm for diagnosis of HIV‐1 infection in peripheral blood mononuclear cells | |
| CA2039449A1 (fr) | Vih-1 amorce et methode de detection a l'aide de l'amorce | |
| Krone et al. | Detection and characterization of HIV-1 by polymerase chain reaction | |
| Damond et al. | Highly sensitive method for amplification of human immunodeficiency virus type 2 DNA | |
| Dyster et al. | Microplate-based DNA hybridization assays for detection of human retroviral gene sequences | |
| Cassol et al. | Improved detection of HIV-1 envelope sequences using optimized PCR and inosine-substituted primers | |
| US6566102B1 (en) | Methods and devices for detection of xenogeneic graft persistence and infectious agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued | ||
| FZDE | Discontinued |
Effective date: 19940928 |